

ATRION CORP
Form 10-Q
November 04, 2009

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q

Quarterly Report Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Quarterly Period Ended September 30, 2009

or

Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Transition Period from to

Commission File Number 0-10763

Atrion Corporation
(Exact Name of Registrant as Specified in its Charter)

Delaware
(State or Other Jurisdiction of
Incorporation or Organization)

63-0821819
(I.R.S. Employer
Identification No.)

One Allentown Parkway, Allen, Texas 75002
(Address of Principal Executive Offices) (Zip Code)

(972) 390-9800
(Registrant's Telephone Number, Including Area Code)

Indicate by check whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definitions of "accelerated filer," "large accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act (Check one):

Large accelerated filer Accelerated filer Non-accelerated filer Smaller reporting company

Indicate by check whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.

Edgar Filing: ATRION CORP - Form 10-Q

| Title of Each Class | Number of Shares Outstanding at October 22, 2009 |
|--|---|
| Common stock, Par Value \$0.10 per share | 1,979,771 |

ATRION CORPORATION AND SUBSIDIARIES

TABLE OF CONTENTS

| | |
|---|-----------|
| PART I. Financial Information | <u>2</u> |
| Item 1. Financial Statements | |
| Consolidated Statements of Income (Unaudited) For the Three and Nine months Ended September 30, 2009 and 2008 | <u>3</u> |
| Consolidated Balance Sheets (Unaudited) September 30, 2009 and December 31, 2008 | <u>4</u> |
| Consolidated Statements of Cash Flows (Unaudited) For the Nine months Ended September 30, 2009 and 2008 | <u>5</u> |
| Notes to Consolidated Financial Statements (Unaudited) | <u>6</u> |
| Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations | <u>9</u> |
| Item 3. Quantitative and Qualitative Disclosures About Market Risk | <u>14</u> |
| Item 4. Controls and Procedures | <u>14</u> |
| PART II. Other Information | <u>15</u> |
| Item 1. Legal Proceedings | <u>15</u> |
| Item 1A. Risk Factors | <u>15</u> |
| Item 2. Unregistered Sales of Equity Securities and Use of Proceeds | <u>15</u> |
| Item 6. Exhibits | <u>16</u> |
| SIGNATURES | <u>17</u> |

PART I

FINANCIAL INFORMATION

Item 1. Financial Statements

ATRION CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF INCOME
(Unaudited)

| | Three Months Ended | | Nine Months Ended | |
|---|--------------------|-----------|-------------------|-----------|
| | September 30, | | September 30, | |
| | 2009 | 2008 | 2009 | 2008 |
| (in thousands, except per share amounts) | | | | |
| Revenues | \$ 25,192 | \$ 23,461 | \$ 76,240 | \$ 72,305 |
| Cost of goods sold | 13,973 | 13,221 | 41,902 | 40,279 |
| Gross profit | 11,219 | 10,240 | 34,338 | 32,026 |
| Operating expenses: | | | | |
| Selling | 1,357 | 1,432 | 4,367 | 4,777 |
| General and administrative | 2,635 | 2,398 | 8,069 | 7,644 |
| Research and development | 661 | 630 | 2,191 | 2,241 |
| | 4,653 | 4,460 | 14,627 | 14,662 |
| Operating income | 6,566 | 5,780 | 19,711 | 17,364 |
| Other income: | | | | |
| Interest income | 162 | 78 | 391 | 164 |
| Other income | -- | -- | 1 | 1 |
| | 162 | 78 | 392 | 165 |
| Income before provision for income taxes | 6,728 | 5,858 | 20,103 | 17,529 |
| Provision for income taxes | (2,268) | (1,866) | (6,852) | (5,746) |
| Net income | \$ 4,460 | \$ 3,992 | \$ 13,251 | \$ 11,783 |
| Income per basic share | \$ 2.25 | \$ 2.03 | \$ 6.70 | \$ 6.02 |
| Weighted average basic shares outstanding | 1,980 | 1,968 | 1,978 | 1,958 |
| Income per diluted share | \$ 2.20 | \$ 1.99 | \$ 6.57 | \$ 5.88 |
| Weighted average diluted shares outstanding | 2,028 | 2,005 | 2,017 | 2,005 |
| Dividends per common share | \$ 0.36 | \$ 0.30 | \$ 0.96 | \$ 0.78 |

The accompanying notes are an integral part of these statements.

ATRION CORPORATION AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(Unaudited)

| Assets | September 30, 2009 | December 31, 2008 |
|--|--------------------------|-------------------------|
| | (in thousands) | |
| Current assets: | | |
| Cash and cash equivalents | \$ 14,313 | \$ 12,056 |
| Short-term investments | 4,860 | 4,692 |
| Accounts receivable | 11,663 | 10,875 |
| Inventories | 18,866 | 20,169 |
| Prepaid expenses | 1,094 | 719 |
| Deferred income taxes | 596 | 596 |
| | 51,392 | 49,107 |
| Long-term investments | 11,537 | -- |
| Property, plant and equipment | 98,768 | 94,364 |
| Less accumulated depreciation and amortization | 44,875 | 40,994 |
| | 53,893 | 53,370 |
| Other assets and deferred charges: | | |
| Patents | 1,644 | 1,863 |
| Goodwill | 9,730 | 9,730 |
| Other | 1,097 | 1,283 |
| | 12,471 | 12,876 |
| | \$ 129,293 | \$ 115,353 |
| Liabilities and Stockholders' Equity | | |
| Current liabilities: | | |
| Accounts payable and accrued liabilities | \$ 6,478 | \$ 5,482 |
| Accrued income and other taxes | 645 | 731 |
| | 7,123 | 6,213 |
| Line of credit | -- | -- |
| Other non-current liabilities | 9,038 | 8,298 |
| Stockholders' equity: | | |
| Common shares, par value \$0.10 per share; authorized 10,000 shares, issued 3,420 shares | 342 | 342 |
| Paid-in capital | 20,166 | 19,130 |
| Accumulated other comprehensive loss | (533) | (533) |

Edgar Filing: ATRION CORP - Form 10-Q

| | | |
|--|------------|------------|
| Retained earnings | 128,894 | 117,554 |
| Treasury shares, 1,440 at September 30, 2009 and 1,452 at December 31, 2008, at cost | (35,737) | (35,651) |
| Total stockholders' equity | 113,132 | 100,842 |
| | | |
| | \$ 129,293 | \$ 115,353 |

The accompanying notes are an integral part of these financial statements.

ATRION CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)

| | Nine months Ended September 30, | |
|---|------------------------------------|-----------|
| | 2009 | 2008 |
| | (in thousands) | |
| Cash flows from operating activities: | | |
| Net income | \$ 13,251 | \$ 11,783 |
| Adjustments to reconcile net income to net cash provided by operating activities: | | |
| Depreciation and amortization | 5,126 | 4,688 |
| Deferred income taxes | 771 | 722 |
| Stock-based compensation | 500 | 482 |
| Other | -- | 37 |
| | 19,648 | 17,712 |
| Changes in operating assets and liabilities: | | |
| Accounts receivable | (788) | (2,118) |
| Inventories | 1,303 | (3,986) |
| Prepaid expenses | (375) | 427 |
| Other non-current assets | 186 | (149) |
| Accounts payable and accrued liabilities | 996 | 549 |
| Accrued income and other taxes | (86) | 481 |
| Other non-current liabilities | (31) | (133) |
| | 20,853 | 12,783 |
| Cash flows from investing activities: | | |
| Property, plant and equipment additions | (5,430) | (4,556) |
| Purchases of investments | (15,705) | (625) |
| Proceeds from investments | 4,000 | -- |
| | (17,135) | (5,181) |
| Cash flows from financing activities: | | |
| Line of credit advances | -- | 3,000 |
| Line of credit repayments | -- | -- |
| Exercise of stock options | 459 | 525 |
| Shares tendered for employees' taxes on stock-based compensation | (122) | (913) |
| Tax benefit related to stock options | 102 | 1,632 |
| Dividends paid | (1,900) | (1,532) |
| | (1,461) | 2,712 |
| Net change in cash and cash equivalents | 2,257 | 10,314 |
| Cash and cash equivalents at beginning of period | 12,056 | 3,531 |
| Cash and cash equivalents at end of period | \$ 14,313 | \$ 13,845 |

Cash paid for:

| | | | | |
|--------------|----|-------|----|-------|
| Income taxes | \$ | 6,394 | \$ | 2,616 |
|--------------|----|-------|----|-------|

The accompanying notes are an integral part of these financial statements.

5

ATRION CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

(1) Basis of Presentation

In the opinion of management, all adjustments necessary for a fair presentation of results of operations for the periods presented have been included in the accompanying unaudited consolidated financial statements of Atrion Corporation and its subsidiaries (the "Company"). Such adjustments consist of normal recurring items. The accompanying financial statements have been prepared in accordance with the instructions to Form 10-Q and include the information and notes required by such instructions. Accordingly, the consolidated financial statements and notes thereto should be read in conjunction with the financial statements and notes included in the Company's 2008 Annual Report on Form 10-K.

(2) Inventories

Inventories are stated at the lower of cost or market. Cost is determined by using the first-in, first-out method. The following table details the major components of inventories (in thousands):

| | September 30, 2009 | December 31, 2008 |
|-------------------|--------------------------|-------------------------|
| Raw materials | \$ 8,114 | \$ 8,978 |
| Work in process | 4,422 | 4,579 |
| Finished goods | 6,330 | 6,612 |
| Total inventories | \$ 18,866 | \$ 20,169 |

(3) Income per share

The following is the computation for basic and diluted income per share:

| | Three months ended September 30, | | Nine months ended September 30, | |
|---|--|----------|------------------------------------|-----------|
| | 2009 | 2008 | 2009 | 2008 |
| | (in thousands, except per share amounts) | | | |
| Net income | \$ 4,460 | \$ 3,992 | \$ 13,251 | \$ 11,783 |
| Weighted average basic shares outstanding | 1,980 | 1,968 | 1,978 | 1,958 |
| Add: Effect of dilutive securities | 48 | 37 | 39 | 47 |
| Weighted average diluted shares outstanding | 2,028 | 2,005 | 2,017 | 2,005 |

Earnings per
share:

| | | | | | | | | |
|---------|----|------|----|------|----|------|----|------|
| Basic | \$ | 2.25 | \$ | 2.03 | \$ | 6.70 | \$ | 6.02 |
| Diluted | \$ | 2.20 | \$ | 1.99 | \$ | 6.57 | \$ | 5.88 |

Outstanding options, restricted stock or deferred stock units that were not included in the diluted income per share calculation because their effect would be anti-dilutive totaled 20,336 for the three-month and nine-month periods ended September 30, 2008, respectively, and none for the same periods in 2009.

ATRION CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

(4) Investments

As of September 30, 2009, the Company held certain investments that are required to be measured for disclosure purposes at fair value on a recurring basis. These investments are considered Level 2 assets as defined by Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 820, Fair Value Measurements and Disclosures. The Company considers as current assets those investments which will mature or are likely to be sold in the next 12 months. The remaining investments are considered non-current assets. The amortized cost and fair value of the Company’s investments that are being accounted for as held-to-maturity securities, and the related gross unrealized gains and losses, were as follows as of September 30, 2009 (in thousands):

| | Cost | Gross Unrealized | | Fair Value |
|---|-----------|------------------|---------|------------|
| | | Gains | Losses | |
| Short-term Investments: | | | | |
| Corporate bonds | \$ 1,201 | \$ 3 | —\$ | 1,204 |
| Bank certificates of deposit | 3,021 | — | — | 3,021 |
| Municipal tax-exempt bonds | 638 | 2 | — | 640 |
| Short-term investment securities held to maturity | \$ 4,860 | \$ 5 | —\$ | 4,865 |
| Long-term Investments | | | | |
| Corporate bonds | \$ 11,537 | \$ 94 | \$ (15) | \$ 11,616 |

At September 30, 2009, the length of time until maturity for the short-term securities ranged from two to ten months. At September 30, 2009, the length of time until maturity for the long-term securities ranged from 16 to 30 months.

(5) Subsequent Events

Effective April 1, 2009, the Company adopted FASB ASC 855-10, Subsequent Events – Overall (“ASC 855-10”). ASC 855-10 establishes general standards of accounting for and disclosure of events that occur after the balance sheet date but before financial statements are issued or are available to be issued. Adoption of ASC 855-10 did not have a material impact on the Company’s consolidated financial statements. The Company evaluated all events or transactions that occurred after September 30, 2009 through November 4, 2009, the date the Company issued these financial statements. During this period the Company did not have any material recognizable subsequent events.

ATRION CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

(6) Pension Benefits

The components of net periodic pension cost for the Atrion Corporation Cash Balance Plan (the “Plan”) are as follows (in thousands):

| | Three Months ended | | Nine Months ended | |
|----------------------------------|--------------------|-------------|-------------------|--------------|
| | September 30, | | September 30, | |
| | 2009 | 2008 | 2009 | 2008 |
| Service cost | \$ -- | \$ -- | \$ -- | \$ -- |
| Interest cost | 54 | 56 | 162 | 168 |
| Expected return on assets | (54) | (55) | (162) | (165) |
| Prior service cost amortization | -- | -- | -- | -- |
| Actuarial loss | 8 | 8 | 24 | 24 |
| Net periodic pension cost | \$ 8 | \$ 9 | \$ 24 | \$ 27 |

In September 2007, the Company terminated the Plan. Participants accrued pension benefits through December 31, 2007, but did not accrue any additional benefits under the Plan after that date. However, participants will continue to earn interest credits on their account balances until the Plan has settled all its obligations with respect to termination. The Company believes that the Plan is adequately funded to cover its settlement obligations. The Company will recognize its remaining net unrecognized actuarial loss as a settlement loss in the fourth quarter of 2009.

(7) Recent Accounting Pronouncements

Effective July 1, 2009, the Company adopted FASB ASC 105-10, Generally Accepted Accounting Principles – Overall (“ASC 105-10”). ASC 105-10 establishes the FASB Accounting Standards Codification (the “Codification”) as the source of authoritative accounting principles recognized by the FASB to be applied by nongovernmental entities in the preparation of financial statements in conformity with U.S. GAAP. Rules and interpretive releases of the SEC under authority of federal securities laws are also sources of authoritative U.S. GAAP for SEC registrants. All guidance contained in the Codification carries an equal level of authority. The Codification superseded all existing non-SEC accounting and reporting standards. All other non-grandfathered, non-SEC accounting literature not included in the Codification is non-authoritative. The FASB will not issue new standards in the form of Statements, FASB Staff Positions or Emerging Issues Task Force Abstracts. Instead, it will issue Accounting Standards Updates (“ASUs”). The FASB will not consider ASUs as authoritative in their own right. ASUs will serve only to update the Codification, provide background information about the guidance and provide the bases for conclusions on the change(s) in the Codification. References made to FASB guidance throughout this document have been updated for the Codification.

From time to time, new accounting standards updates applicable to the Company are issued by the FASB, which the Company will adopt as of the specified effective date. Unless otherwise discussed, the Company believes the impact of recently issued standards updates that are not yet effective will not have a material impact on its consolidated financial statements upon adoption.

Item Management's Discussion and Analysis of Financial Condition and Results of Operations

2.

Overview

The Company develops and manufactures products primarily for medical applications. The Company markets components to other equipment manufacturers for incorporation in their products and sells finished devices to physicians, hospitals, clinics and other treatment centers. The Company's medical products primarily serve the fluid delivery, cardiovascular, and ophthalmology markets. The Company's other medical and non-medical products include instrumentation and disposables used in dialysis, contract manufacturing and valves and inflation devices used in marine and aviation safety products.

The Company's products are used in a wide variety of applications by numerous customers. The Company encounters competition in all of its markets and competes primarily on the basis of product quality, price, engineering, customer service and delivery time.

The Company's strategy is to provide a broad selection of products in the areas of its expertise. Research and development efforts are focused on improving current products and developing highly-engineered products that meet customer needs and have the potential for broad market applications and significant sales. Proposed new products may be subject to regulatory clearance or approval prior to commercialization and the time period for introducing a new product to the marketplace can be unpredictable. The Company also focuses on controlling costs by investing in modern manufacturing technologies and controlling purchasing processes. The Company has been successful in consistently generating cash from operations and has used that cash to reduce indebtedness, to fund capital expenditures, to repurchase stock and to pay dividends.

The Company's strategic objective is to further enhance its position in its served markets by:

- Focusing on customer needs;
- Expanding existing product lines and developing new products;
- Maintaining a culture of controlling cost; and
- Preserving and fostering a collaborative, entrepreneurial management structure.

For the three months ended September 30, 2009, the Company reported revenues of \$25.2 million, operating income of \$6.6 million and net income of \$4.5 million, up 7 percent, 14 percent and 12 percent, respectively, from the three months ended September 30, 2008. For the nine months ended September 30, 2009, the Company reported revenues of \$76.2 million, operating income of \$19.7 million and net income of \$13.3 million, up 5 percent, 14 percent and 13 percent, respectively, from the nine months ended September 30, 2008.

Results for the three months ended September 30, 2009

Consolidated net income totaled \$4.5 million, or \$2.25 per basic and \$2.20 per diluted share, in the third quarter of 2009. This is compared with consolidated net income of \$4.0 million, or \$2.03 per basic and \$1.99 per diluted share, in the third quarter of 2008. The income per basic share computations are based on weighted average basic shares outstanding of 1,979,943 in the 2009 period and 1,967,669 in the 2008 period. The income per diluted share computations are based on weighted average diluted shares outstanding of 2,027,884 in the 2009 period and 2,005,295 in the 2008 period.

Consolidated revenues of \$25.2 million for the third quarter of 2009 were 7 percent higher than revenues of \$23.5 million for the third quarter of 2008. This increase was generally attributable to higher sales volumes and increased prices.

Revenues by product line were as follows (in thousands):

| | Three Months ended September 30, | |
|----------------|-------------------------------------|-----------|
| | 2009 | 2008 |
| Fluid Delivery | \$ 9,535 | \$ 7,999 |
| Cardiovascular | 6,948 | 7,019 |
| Ophthalmology | 4,418 | 3,733 |
| Other | 4,291 | 4,710 |
| Total | \$ 25,192 | \$ 23,461 |

Cost of goods sold of \$14.0 million for the third quarter of 2009 was \$752,000 higher than in the comparable 2008 period. The primary contributor to this increase was higher sales volume. The Company's cost of goods sold in the third quarter of 2009 was 55.5 percent of revenues compared with 56.4 percent of revenues in the third quarter of 2008.

Gross profit of \$11.2 million in the third quarter of 2009 was \$979,000, or 10 percent, higher than in the comparable 2008 period. The Company's gross profit percentage in the third quarter of 2009 was 44.5 percent of revenues compared with 43.6 percent of revenues in the third quarter of 2008. The increase in gross profit percentage in the 2009 period compared to the 2008 period was primarily related to improved product mix and cost improvement initiatives.

The Company's third quarter 2009 operating expenses of \$4.7 million were \$193,000 higher than the operating expenses for the third quarter of 2008. This increase was comprised of a \$237,000 increase in General and Administrative (G&A) expenses and a \$31,000 increase in Research and Development (R&D) expenses partially offset by a \$75,000 decrease in Selling (Selling) expenses. The increase in G&A expenses for the third quarter of 2009 was principally attributable to increased compensation, increased outside services and increased taxes partially offset by reduced travel. The increase in R&D costs was primarily related to outside services and compensation. The decrease in Selling expenses for the third quarter of 2009 was primarily related to decreased promotion and travel-related expenses partially offset by increased compensation.

Operating income in the third quarter of 2009 increased \$786,000 to \$6.6 million, a 14 percent increase over operating income in the quarter ended September 30, 2008. Operating income was 26 percent of revenues in the third quarter of 2009 compared to 25 percent of revenues in the third quarter of 2008. The major contributor to the operating income improvement in the third quarter of 2009 was the previously mentioned increase in gross profit partially offset by the slight increase in operating expenses.

Income tax expense for the third quarter of 2009 was \$2.3 million compared to income tax expense of \$1.9 million for the same period in the prior year. The effective tax rate for the third quarter of 2009 was 33.7 percent, compared with 31.9 percent for the third quarter of 2008. The increase in the effective tax rate for the 2009 period is primarily a result of benefits from tax incentives for R&D expenditures being a smaller percentage of taxable income than in the third quarter of 2008 and an increase in state income taxes in the 2009 period. The Company expects the effective tax rate for the remainder of 2009 to be within a range of 33.0 to 34.0 percent.

Results for the nine months ended September 30, 2009

Consolidated net income totaled \$13.3 million, or \$6.70 per basic and \$6.57 per diluted share, in the first nine months of 2009. This is compared with consolidated net income of \$11.8 million, or \$6.02 per basic and \$5.88 per diluted share, in the first nine months of 2008. The income per basic share computations are based on weighted average basic shares outstanding of 1,977,901 in the 2009 period and 1,958,626 in the 2008 period. The income per diluted share computations are based on weighted average diluted shares outstanding of 2,017,414 in the 2009 period and 2,004,517 in the 2008 period.

Consolidated revenues of \$76.2 million for the first nine months of 2009 were 5 percent higher than revenues of \$72.3 million for the first nine months of 2008. This increase was generally attributable to higher sales volumes and increased prices.

Revenues by product line were as follows (in thousands):

| | Nine Months ended September 30, | |
|----------------|------------------------------------|-----------|
| | 2009 | 2008 |
| Fluid Delivery | \$ 27,685 | \$ 24,896 |
| Cardiovascular | 21,439 | 21,602 |
| Ophthalmology | 14,948 | 11,101 |
| Other | 12,168 | 14,706 |
| Total | \$ 76,240 | \$ 72,305 |

Cost of goods sold of \$41.9 million for the first nine months of 2009 was \$1.6 million higher than in the comparable 2008 period. The primary contributor to this increase was higher sales volume. The Company's cost of goods sold in the first nine months of 2009 was 55.0 percent of revenues compared with 55.7 percent of revenues in the first nine months of 2008.

Gross profit of \$34.3 million in the first nine months of 2009 was \$2.3 million, or 7 percent, higher than in the comparable 2008 period. The Company's gross profit percentage in the first nine months of 2009 was 45.0 percent of revenues compared with 44.3 percent of revenues in the first nine months of 2008. The increase in gross profit percentage in the 2009 period compared to the 2008 period was primarily related to improved product mix and cost improvement initiatives.

Operating expenses of \$14.6 million for the first nine months of 2009 were \$35,000 lower than the operating expenses for the comparable period in 2008. This decrease was comprised of a \$410,000 decrease in Selling expenses and a \$50,000 decrease in R&D expenses largely offset by a \$425,000 increase in G&A expenses. The decrease in Selling expenses for the first nine months of 2009 was primarily related to decreased compensation, promotion, outside services, and travel-related expenses. The decrease in R&D costs was primarily related to reduced prototype expenses. The increase in G&A expenses for the first nine months of 2009 was principally attributable to increased compensation and outside services partially offset by decreased travel-related expenses.

Operating income in the first nine months of 2009 increased \$2.3 million to \$19.7 million, a 14 percent increase over operating income in the nine months ended September 30, 2008. Operating income was 26 percent of revenues in the first nine months of 2009 compared to 24 percent of revenues in the first nine months of 2008. The previously mentioned increase in gross profit coupled with the decrease in operating expenses were the major contributors to the operating income improvement in the first nine months of 2009.

Income tax expense for the first nine months of 2009 was \$6.9 million compared to income tax expense of \$5.7 million for the same period in the prior year. The effective tax rate for the first nine months of 2009 was 34.1 percent, compared with 32.8 percent for the first nine months of 2008. The increase in the effective tax rate for 2009 is primarily a result of benefits from tax incentives for R&D expenditures being a smaller percentage of taxable income and an increase in state income taxes. The Company expects the effective tax rate for the remainder of 2009 to be within a range of 33.0 to 34.0 percent.

Liquidity and Capital Resources

The Company has a \$25.0 million revolving credit facility (the "Credit Facility") with a money center bank to be utilized for the funding of operations and for major capital projects or acquisitions, subject to certain limitations and restrictions. Borrowings under the Credit Facility bear interest that is payable monthly at 30-day, 60-day or 90-day LIBOR, as selected by the Company, plus one percent. The Company had no outstanding borrowings under its Credit Facility at September 30, 2009 or at December 31, 2008. The Credit Facility, which expires November 12, 2012, and may be extended under certain circumstances, contains various restrictive covenants, none of which is expected to impact the Company's liquidity or capital resources. At September 30, 2009, the Company was in compliance with all financial covenants and had \$25.0 million available for borrowing under the Credit Facility. The Company believes that the bank providing the Credit Facility is highly-rated and that the entire \$25.0 million under the Credit Facility is currently available to the Company. If that bank were unable to provide such funds, the Company believes that such inability would not impact the Company's ability to fund operations.

At September 30, 2009, the Company had \$30.7 million in cash and cash equivalents and short-term and long-term investments, an increase of \$14.0 million from December 31, 2008. The principal contributor to this increase was the cash generated by operating activities of \$20.9 million, which was partially offset by payments for acquisitions of property, plant, and equipment of \$5.4 million and the payment of dividends of \$1.9 million

As of September 30, 2009, the Company had working capital of \$44.3 million, including \$14.3 million in cash and cash equivalents. The \$1.4 million increase in working capital during the first nine months of 2009 was primarily related to increases in cash and short-term investments and increases in accounts receivable partially offset by decreases to inventories and an increase in accounts payable and accrued liabilities. The increase in accounts receivable was primarily related to the increase in revenues for the third quarter of 2009 as compared with the fourth quarter of 2008. The decrease in inventories was primarily related to the Company's consumption of raw materials purchased in 2008 under a program to hedge against future price increases. The increase in accounts payable and accrued liabilities was primarily related to routine amounts due to suppliers partially offset by reductions in accrued compensation.

Cash flows from operating activities generated \$20.8 million for the nine months ended September 30, 2009 as compared to \$12.8 million for the nine months ended September 30, 2008. The increase in the 2009 period was primarily attributable to increased operational results and more favorable cash requirements for working capital related to inventories and accounts receivables as compared to the 2008 period. During the first nine months of 2009, the Company expended \$5.4 million for the addition of property and equipment and \$15.7 million for short-term and long-term investments. Stock option activities in the first nine months of 2009 generated \$439,000 of cash and the Company paid dividends of \$1.9 million during that period.

Although the recent distress in the financial markets and the global economy in general has not had a significant impact on the Company's liquidity, the Company continues to monitor the financial markets and general global economic conditions. In the current credit and financial markets, many companies are finding it difficult to gain access to capital resources. In spite of the current economic conditions, the Company believes that its \$19.2 million in cash, cash equivalents and short-term investments, \$11.5 million in long-term investments, cash flows from operations and available borrowings of up to \$25.0 million under the Company's Credit Facility will be sufficient to fund the Company's cash requirements for at least the foreseeable future. The Company believes that its strong financial position would allow it to access equity or debt financing should that be necessary and its capital resources should not be materially impacted by the current economic crisis. Additionally, the Company believes that its cash and cash equivalents, short-term investments and long-term investments, as a whole, will continue to increase in the remainder of 2009.

Forward-Looking Statements

Statements in this Management's Discussion and Analysis that are forward-looking are based upon current expectations, and actual results may differ materially. Therefore, the inclusion of such forward-looking information should not be regarded as a representation by the Company that the objectives or plans of the Company would be achieved. Such statements include, but are not limited to, the Company's expectations regarding the effective tax rate for the remainder of 2009, the Company's ability to fund its cash requirements for the foreseeable future with its current assets, long-term investments, cash flow and borrowings under the Credit Facility, the impact that a failure of the bank providing the Credit Facility would have on the Company's ability to fund operations, the Company's access to equity and debt financing, the impact of the current economic crisis on the Company's capital resources and the increase in cash, cash equivalents, short-term investments and long-term investments in the remainder of 2009. Words such as "anticipates," "believes," "expects," "estimated" and variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements contained herein involve numerous risks and uncertainties, and there are a number of factors that could cause actual results or future events to differ materially, including, but not limited to, the following: changing economic, market and business conditions; acts of war or terrorism; the effects of governmental regulation; the impact of competition and new technologies; slower-than-anticipated introduction of new products or implementation of marketing strategies; implementation of new manufacturing processes or implementation of new information systems; the Company's ability to protect its intellectual property; changes in the prices of raw materials; changes in product mix; intellectual property and product liability claims and product recalls; the ability to attract and retain qualified personnel; and the loss of, or any material reduction in sales to, any significant customers. In addition, assumptions relating to budgeting, marketing, product development and other management decisions are subjective in many respects and thus susceptible to interpretations and periodic review which may cause the Company to alter its marketing, capital expenditures or other budgets, which in turn may affect the Company's results of operations and financial condition.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

For the quarter ended September 30, 2009, the Company did not experience any material changes in market risk exposures that affect the quantitative and qualitative disclosures presented in the Company's 2008 Annual Report on Form 10-K.

Item 4. Controls and Procedures

The Company's management, with the participation of the Company's Chief Executive Officer and its Chief Financial Officer, evaluated the Company's disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of September 30, 2009. Based upon this evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that the Company's disclosure controls and procedures are effective. There were no changes in the Company's internal control over financial reporting for the quarter ended September 30, 2009 that have materially affected or are reasonably likely to materially affect the Company's internal control over financial reporting.

PART II

OTHER INFORMATION

Item 1. Legal Proceedings

From time to time, the Company may be involved in claims or litigation that arise in the normal course of business. The Company is not currently a party to any legal proceedings, which, if decided adversely, would have a material adverse effect on the Company's business, financial condition, or results of operations.

Item 1A. Risk Factors

There were no material changes to Risk Factors disclosed in our annual report on Form 10-K for the year ended December 31, 2008.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

| Period | Total Number of Shares Purchased | Average Price Paid per Share | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs | Maximum Number of Shares that May Yet Be Purchased Under the Plans or Programs (1) |
|----------------------------|--|---------------------------------|--|--|
| 7/1/2009 through 7/31/2009 | -- | -- | -- | 68,100 |
| 8/1/2009 through 8/31/2009 | 400(2) | \$ 130.06 | -- | 68,100 |
| 9/1/2009 through 9/30/2009 | -- | -- | -- | 68,100 |
| Total | 400 | \$ 130.06 | -- | 68,100 |

- (1) The Company has a program that was announced in April 2000 to purchase in open market or privately negotiated transactions up to 200,000 shares. The program has no expiration date but may be terminated at any time by the Board of Directors.
- (2) Consists of shares delivered to the Company in payment of income taxes related to vesting of restricted stock by a participant in a Company equity incentive plan. The Company's equity incentive plans permit a participant under certain circumstances to deliver shares of Company stock in payment of income taxes due to be paid on equity awards.

Item 6. Exhibits

Exhibit

Number Description

31.1 Sarbanes-Oxley Act Section 302 Certification of Chief Executive Officer

31.2 Sarbanes-Oxley Act Section 302 Certification of Chief Financial Officer

32.1 Certification Pursuant To 18 U.S.C. Section 1350, As Adopted Pursuant To Section 906 of The Sarbanes – Oxley Act Of 2002

32.2 Certification Pursuant To 18 U.S.C. Section 1350, As Adopted Pursuant To Section 906 of The Sarbanes – Oxley Act Of 2002

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Atrion Corporation
(Registrant)

Date: November 4, 2009

By: /s/ Emile A. Battat
Emile A. Battat
Chairman and
Chief Executive Officer

Date: November 4, 2009

By: /s/ Jeffery Strickland
Jeffery Strickland
Vice President and
Chief Financial Officer